Methylphenidate (MPH) is the first-line treatment for Attention-Deficit/Hyperactivity Disorder (ADHD), a condition that disrupts daily functioning. Research indicates that individuals with ADHD often experience sensory processing impairments, regardless of co-occurring conditions. Given the growing interest in pharmacogenetics to personalise treatments and minimise side effects, this study aims to characterise the sensory profiles of in child and youth ADHD patients treated with MPH and…
